Pulse Biosciences (NASDAQ:PLSE – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.21) earnings per share for the quarter, RTT News reports. During the same quarter in the prior year, the business posted ($0.19) EPS.
Pulse Biosciences Stock Down 1.3 %
PLSE stock opened at $17.20 on Friday. Pulse Biosciences has a fifty-two week low of $4.35 and a fifty-two week high of $22.69. The business has a 50-day moving average of $17.62 and a 200-day moving average of $14.24.
Analyst Ratings Changes
Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Friday, September 20th.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
- Five stocks we like better than Pulse Biosciences
- Consumer Staples Stocks, Explained
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Top Nuclear Stocks Thriving on Soaring Energy Demand
- What Do S&P 500 Stocks Tell Investors About the Market?
- Apple Earnings – When Really Good Just Isn’t Good Enough
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png?v=20240923123417&h=45&w=95&zc=2){kind=logo}